Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REASON study of guselkumab for transmural healing in active Crohn's disease
MOH_2023-11-30_013088Phase 3Not yet recruiting
- Sponsor
- Johnson & Johnson
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of guselkumab in Crohn's disease, sponsored by Johnson & Johnson. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2023-11-30_013088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-11-30_013088.